<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39433805</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>New insights in the mechanism of the SARS-CoV-2 M<sup>pro</sup> inhibition by benzisoselenazolones and diselenides.</ArticleTitle><Pagination><StartPage>24751</StartPage><MedlinePgn>24751</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24751</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75519-6</ELocationID><Abstract><AbstractText>Although global vaccination campaigns alleviated the SARS-CoV-2 pandemic in terms of morbidity and mortality, the ability of the virus to originate mutants may reduce the efficacy of vaccines, posing a serious risk of a renewed pandemic. There is therefore a need to develop small molecules capable of targeting conserved viral targets, such as the main protease (M<sup>pro</sup>). Here, a series of benzisoselenazolones and diselenides were tested for their ability to inhibit M<sup>pro</sup>; then the most potent compounds were measured for antiviral activity in vitro, and the mechanism of action was investigated. Density functional theory calculations, molecular docking and molecular dynamics simulations were also used to elucidate the protein/drug interaction. Finally, a bio-organic model was established to study the reaction between selenorganic compounds and biologically relevant thiols to unveil possible metabolic pathways of such compounds. The overall results contribute to the identification of a series of novel Se-containing molecules active against SARS-CoV-2 and to the clarification of some important aspects in the mechanisms of action of such inhibitors targeting SARS-CoV-2 M<sup>pro</sup>.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sancineto</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06100, PG, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangiavacchi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06100, PG, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabrowska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, Krakow, 30-387, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, Krakow, 30-387, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacuła-Miszewska</LastName><ForeName>Agata J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, Torun, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obieziurska-Fabisiak</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, Torun, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scimmi</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06100, PG, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccucci</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06100, PG, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciancaleoni</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Chimica e Chimica Industriale (DCCI), Università di Pisa, Via Giuseppe Moruzzi, 13, Pisa, 56124, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departamento de Quımica Organica, Laboratorio de Sintese e Aplicaçao de Substancias Supramoleculares e Organocalcogenios (SupraSelen), Universidade Federal Fluminense, Outeiro Sao Joao Batista s/n, Niteroi, 24020-141, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzuti</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Physics, CNR-NANOTEC, SS Rende, University of Calabria, Rende, 87036, CS, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biocomputation and Physics of Complex Systems, Joint Unit GBsC-CSIC-BIFI, University of Zaragoza, Zaragoza, 50018, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortoli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Hylleraas Centre for Quantum Molecular Sciences, University of Oslo, Oslo, 0315, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orian</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Chimiche, Università degli Studi di Padova, Padova, 35131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kula-Pacurar</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, Krakow, 30-387, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ścianowski</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, Torun, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. leiying@shanghaitech.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyrc</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, Krakow, 30-387, Poland. k.a.pyrc@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06100, PG, Italy. claudio.santi@unipg.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Dipartimenti di Eccellenza 2018-2022</GrantID><Agency>Ministero dell'Istruzione, dell'Università e della Ricerca</Agency><Country /></Grant><Grant><GrantID>Dipartimenti di Eccellenza 2018-2022</GrantID><Agency>Ministero dell'Istruzione, dell'Università e della Ricerca</Agency><Country /></Grant><Grant><GrantID>Dipartimenti di Eccellenza 2018-2022</GrantID><Agency>Ministero dell'Istruzione, dell'Università e della Ricerca</Agency><Country /></Grant><Grant><GrantID>Ricerca di Base</GrantID><Agency>University of Perugia</Agency><Country /></Grant><Grant><GrantID>Ricerca di Base</GrantID><Agency>University of Perugia</Agency><Country /></Grant><Grant><GrantID>Ricerca di Base</GrantID><Agency>University of Perugia</Agency><Country /></Grant><Grant><GrantID>Ricerca di Base</GrantID><Agency>University of Perugia</Agency><Country /></Grant><Grant><GrantID>Ricerca di Base</GrantID><Agency>University of Perugia</Agency><Country /></Grant><Grant><GrantID>DURABLE project</GrantID><Agency>European UNion EU4Health Programme (EU4H)(https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthiereuropean-union_en#work-programmes)</Agency><Country /></Grant><Grant><GrantID>DURABLE project</GrantID><Agency>European UNion EU4Health Programme (EU4H)(https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthiereuropean-union_en#work-programmes)</Agency><Country /></Grant><Grant><GrantID>DURABLE project</GrantID><Agency>European UNion EU4Health Programme (EU4H)(https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthiereuropean-union_en#work-programmes)</Agency><Country /></Grant><Grant><GrantID>ERAnet ICRAD-project</GrantID><Agency>Musecov: Multiscale Eco-evolution of Coronaviruses: from surveillance toward emergence prediction (https://www.era-learn.eu/network-information/networks/icrad/1st-icrad-call-2019/multiscale-eco-evolution-of-coronaviruses-from-surveillance-toward-emergence-prediction)</Agency><Country /></Grant><Grant><GrantID>ERAnet ICRAD-project</GrantID><Agency>Musecov: Multiscale Eco-evolution of Coronaviruses: from surveillance toward emergence prediction (https://www.era-learn.eu/network-information/networks/icrad/1st-icrad-call-2019/multiscale-eco-evolution-of-coronaviruses-from-surveillance-toward-emergence-prediction)</Agency><Country /></Grant><Grant><GrantID>ERAnet ICRAD-project</GrantID><Agency>Musecov: Multiscale Eco-evolution of Coronaviruses: from surveillance toward emergence prediction (https://www.era-learn.eu/network-information/networks/icrad/1st-icrad-call-2019/multiscale-eco-evolution-of-coronaviruses-from-surveillance-toward-emergence-prediction)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016566">Organoselenium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="Y">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016566" MajorTopicYN="Y">Organoselenium Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Benzisoselenazolones</Keyword><Keyword MajorTopicYN="N">Diselenides</Keyword><Keyword MajorTopicYN="N">Ebselen</Keyword><Keyword MajorTopicYN="N">Glutathione</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 main protease inhibitors</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433805</ArticleId><ArticleId IdType="pmc">PMC11494035</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75519-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75519-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peiris, J. S. M., Guan, Y. &amp; Yuen, K. Y. severe acute respiratory syndrome. Nat. Med. 10, S88–S97 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096017</ArticleId><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference><Reference><Citation>Memish, Z. A., Perlman, S., Van Kerkhove, M. D. &amp; Zumla, A. Middle east respiratory syndrome. Lancet. 395, 1063–1077 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155742</ArticleId><ArticleId IdType="pubmed">32145185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannalire, R. et al. SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells. Int. J. Mol. Sci. 21, 5707 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460888</ArticleId><ArticleId IdType="pubmed">32784899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, Z. et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. (2020). 10.1101/2020.02.26.964882</Citation></Reference><Reference><Citation>Nadeem, M. S. et al. Origin, potential therapeutic targets and treatment for Coronavirus Disease (COVID-19). Pathogens. 9, 307 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238035</ArticleId><ArticleId IdType="pubmed">32331255</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos Nascimento, I. J., da Silva-Júnior, E. F. &amp; de Aquino, T. M. Molecular modeling targeting transmembrane serine protease 2 (TMPRSS2) as an Alternative Drug Target against coronaviruses. Curr. Drug Targets. 23, 240–259 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34370633</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Miller, S. et al. Novel compounds Targeting Neuropilin receptor 1 with potential to interfere with SARS-CoV-2 Virus Entry. ACS Chem. Neurosci. 12, 1299–1312 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029449</ArticleId><ArticleId IdType="pubmed">33787218</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, C. Drug researchers pursue new lines of attack against COVID-19. Nat. Biotechnol. 38, 659–662 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32417850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghahremanpour, M. M. et al. Identification of 14 known drugs as inhibitors of the Main protease of SARS-CoV-2. ACS Med. Chem. Lett. 11, 2526–2533 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605328</ArticleId><ArticleId IdType="pubmed">33324471</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen, D. R. et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Sci. (1979). 374, 1586–1593 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, X. et al. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat. Microbiol. 9, 1075–1088 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10994847</ArticleId><ArticleId IdType="pubmed">38553607</ArticleId></ArticleIdList></Reference><Reference><Citation>Saar, K. L. et al. Turning high-throughput structural biology into predictive inhibitor design. Proc. Natl. Acad. Sci. 120, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10089178</ArticleId><ArticleId IdType="pubmed">36877844</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnham, M. J. &amp; Sies, H. The early research and development of ebselen. Biochem. Pharmacol. 86, 1248–1253 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24012716</ArticleId></ArticleIdList></Reference><Reference><Citation>Santi, C., Scimmi, C. &amp; Sancineto, L. Ebselen and analogues: pharmacological properties and synthetic strategies for their Preparation. Molecules. 26, 4230 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8306772</ArticleId><ArticleId IdType="pubmed">34299505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 582, 289–293 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Weglarz-Tomczak, E. et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci. Rep. 11, 3640 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878891</ArticleId><ArticleId IdType="pubmed">33574416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmudzinski, M. et al. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase. Sci. Rep. 13, 9161 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10242237</ArticleId><ArticleId IdType="pubmed">37280236</ArticleId></ArticleIdList></Reference><Reference><Citation>Menéndez, C. A., Byléhn, F., Perez-Lemus, G. R., Alvarado, W. &amp; de Pablo, J. J. Molecular characterization of Ebselen binding activity to SARS-CoV-2 main protease. Sci. Adv. Eabd. 3045. 10.1126/sciadv.abd0345 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486088</ArticleId><ArticleId IdType="pubmed">32917717</ArticleId></ArticleIdList></Reference><Reference><Citation>Węglarz-Tomczak, E., Tomczak, J., Talma, M. &amp; Brul, S. Ebselen as a highly active inhibitor of PL pro CoV2. bioRxiv. 10.1101/2020.05.17.100768 (2020).</Citation></Reference><Reference><Citation>Mukherjee, S. et al. Ebselen inhibits Hepatitis C Virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem. Biol. 9, 2393–2403 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201343</ArticleId><ArticleId IdType="pubmed">25126694</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou, J. et al. Ebselen as a potent covalent inhibitor of New Delhi metallo-β-lactamase (NDM-1). Chem. Commun. 51, 9543–9546 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25970101</ArticleId></ArticleIdList></Reference><Reference><Citation>Favrot, L. et al. Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nat. Commun. 4, 2748 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049535</ArticleId><ArticleId IdType="pubmed">24193546</ArticleId></ArticleIdList></Reference><Reference><Citation>Thenin-Houssier, S. et al. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrob. Agents Chemother. 60, 2195–2208 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808204</ArticleId><ArticleId IdType="pubmed">26810656</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux, F. et al. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur. J. Med. Chem. 179, 557–566 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718346</ArticleId><ArticleId IdType="pubmed">31276900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenardão, E. J., Santi, C. &amp; Sancineto, L. New frontiers in organoselenium compounds (Springer International Publishing, 2018). 10.1007/978-3-319-92405-2</Citation></Reference><Reference><Citation>Sies, H. &amp; Parnham, M. J. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radic Biol. Med. 156, 107–112 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319625</ArticleId><ArticleId IdType="pubmed">32598985</ArticleId></ArticleIdList></Reference><Reference><Citation>Amporndanai, K. et al. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat. Commun. 12, 3061 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8144557</ArticleId><ArticleId IdType="pubmed">34031399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo, P. et al. Detailed insights into the inhibitory mechanism of New Ebselen derivatives against main protease (M pro) of severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). ACS Pharmacol. Transl Sci. 10.1021/acsptsci.2c00203 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9797022</ArticleId><ArticleId IdType="pubmed">36650888</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff, S. et al. Discovery and mechanism of SARS-CoV-2 main protease inhibitors. J. Med. Chem. Acs Jmedchem. 10.1021/acs.jmedchem.1c00566 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491550</ArticleId><ArticleId IdType="pubmed">34570513</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao, Z. et al. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus. Bioorg. Chem. 117, 105455 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556866</ArticleId><ArticleId IdType="pubmed">34740055</ArticleId></ArticleIdList></Reference><Reference><Citation>Abian, O. et al. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol. Macromol. 164, 1693–1703 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395220</ArticleId><ArticleId IdType="pubmed">32745548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangiavacchi, F. et al. Seleno-functionalization of Quercetin improves the non-covalent inhibition of Mpro and its antiviral activity in cells against SARS-CoV-2. Int. J. Mol. Sci. 22, 7048 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268238</ArticleId><ArticleId IdType="pubmed">34208928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes, L. S. et al. Ecofriendly aminochalcogenation of alkenes: a green alternative to obtain compounds with potential anti-SARS-CoV-2 activity. New J. Chem. 10.1039/D2NJ06218F (2023).</Citation></Reference><Reference><Citation>Omage, F. B. et al. Diphenyl diselenide and SARS-CoV-2: in silico exploration of the mechanisms of inhibition of main protease (Mpro) and papain-like protease (PLpro). J. Chem. Inf. Model. 63, 2226–2239 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10091420</ArticleId><ArticleId IdType="pubmed">36952618</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasowska, D. et al. Ultrasound-assisted synthesis of alkali metals diselenides (M2Se2) and their application for the gram-scale preparation of 2,2’-diselenobis(benzoic acid). Arkivoc 24–37 (2019).</Citation></Reference><Reference><Citation>Begini, F. et al. Continuous flow synthesis of 2,2′-diselenobis(benzoic acid) and derivatives. React. Chem. Eng. 5, 641–644 (2020).</Citation></Reference><Reference><Citation>Sancineto, L. et al. Design and synthesis of DiselenoBisBenzamides (DISeBAs) as nucleocapsid protein 7 (NCp7) inhibitors with anti-HIV activity. J. Med. Chem. 58, 9601–9614 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26613134</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento, V. et al. Fast and easy conversion of Ortho amidoaryldiselenides into the corresponding ebselen-like derivatives driven by theoretical investigations. New J. Chem. 44, 9444–9451 (2020).</Citation></Reference><Reference><Citation>Pacuła, A. J. et al. New Chiral Ebselen analogues with antioxidant and cytotoxic potential. Molecules. 22, 492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155185</ArticleId><ArticleId IdType="pubmed">28335518</ArticleId></ArticleIdList></Reference><Reference><Citation>Obieziurska, M. et al. Bioselectivity Induced by Chirality of New Terpenyl Organoselenium compounds. Materials. 12, e3579 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6862013</ArticleId><ArticleId IdType="pubmed">31683558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuti, B. et al. Sub-micromolar inhibition of SARS-CoV-2 3CLpro by natural compounds. Pharmaceuticals. 14, 892 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8465303</ArticleId><ArticleId IdType="pubmed">34577592</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt, J., Santos-Martins, D., Tillack, A. F. &amp; Forli, S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. J. Chem. Inf. Model. 61, 3891–3898 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10683950</ArticleId><ArticleId IdType="pubmed">34278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos Nascimento, I. J., de dos, Aquino, T. M. &amp; Silva-Júnior, E. F. Da. Repurposing FDA-approved drugs targeting SARS-CoV2 3CLpro: a study by applying virtual screening, molecular dynamics, MM-PBSA calculations and covalent docking. Lett. Drug Des. Discov. 19, 637–653 (2022).</Citation></Reference><Reference><Citation>Parise, A., Romeo, I., Russo, N. &amp; Marino, T. The Se–S bond formation in the covalent inhibition mechanism of SARS-CoV-2 main protease by Ebselen-like inhibitors: a computational study. Int. J. Mol. Sci. 22, 9792 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8467846</ArticleId><ArticleId IdType="pubmed">34575955</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabeni, A., Nogara, P. A., Omage, F. B., Rocha, J. B. T. &amp; Orian, L. Mechanistic insight into SARS-CoV-2 Mpro inhibition by Organoselenides: the Ebselen Case Study. Appl. Sci. 11, 6291 (2021).</Citation></Reference><Reference><Citation>Nogueira, C. W., Barbosa, N. V. &amp; Rocha, J. B. T. Toxicology and pharmacology of synthetic organoselenium compounds: an update. Arch. Toxicol. 95, 1179–1226 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012418</ArticleId><ArticleId IdType="pubmed">33792762</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister, A. Glutathione metabolism and its selective modification. J. Biol. Chem. 263, 17205–17208 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3053703</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, M. S. et al. Selenium-NMR spectroscopy in Organic synthesis: from structural characterization toward New investigations. Asian J. Org. Chem. 10, 91–128 (2021).</Citation></Reference><Reference><Citation>Sands, K. N., Burman, A. L., Ansah-Asamoah, E. &amp; Back, T. G. Chemistry related to the Catalytic cycle of the antioxidant Ebselen. Molecules. 28, 3732 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10180093</ArticleId><ArticleId IdType="pubmed">37175141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, C. et al. Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol. Transl Sci. 3, 1265–1277 (2020). Ebselen.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571300</ArticleId><ArticleId IdType="pubmed">33330841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieder, G. S. et al. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2. Comput. Biol. Chem. 107, 107956 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37748316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, C., Tan, H., Choza, J., Wang, Y. &amp; Wang, J. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and protease-glo luciferase assays. Acta Pharm. Sin B. 12, 1636–1651 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8558150</ArticleId><ArticleId IdType="pubmed">34745850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, H., Ma, C. &amp; Wang, J. Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Med. Chem. Res. 31, 1147–1153 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095416</ArticleId><ArticleId IdType="pubmed">35578732</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilmann, E. et al. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Commun. Biol. 5, 391 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046202</ArticleId><ArticleId IdType="pubmed">35478219</ArticleId></ArticleIdList></Reference><Reference><Citation>Neese, F. The ORCA program system. WIREs Comput. Mol. Sci. 2, 73–78 (2012).</Citation></Reference><Reference><Citation>Grimme, S., Ehrlich, S. &amp; Goerigk, L. Effect of the damping function in dispersion corrected density functional theory. J. Comput. Chem. 32, 1456–1465 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21370243</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimme, S., Antony, J., Ehrlich, S. &amp; Krieg, H. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J. Chem. Phys. 132, 1-20 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20423165</ArticleId></ArticleIdList></Reference><Reference><Citation>Glendening, E. D. et al. NBO 7.0. Preprint at (2018).</Citation></Reference><Reference><Citation>Rizzuti, B. et al. Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: implications for drug design of Quercetin Analogs. Biomedicines. 9, 375 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8066963</ArticleId><ArticleId IdType="pubmed">33918402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Sci. (1979). 368, 409–412 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanwell, M. D. et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4, 17 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542060</ArticleId><ArticleId IdType="pubmed">22889332</ArticleId></ArticleIdList></Reference><Reference><Citation>Santofimia-Castaño, P. et al. Intrinsically disordered chromatin protein NUPR1 binds to the C-terminal region of polycomb RING1B. Proc. Natl. Acad. Sci. 114, E6332–E6341 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547589</ArticleId><ArticleId IdType="pubmed">28720707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Wang, W., Kollman, P. A. &amp; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph Model. 25, 247–260 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16458552</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisch, M. J. et al. Gaussian 16, Revision C.01,. Preprint at (2016).</Citation></Reference><Reference><Citation>Fellowes, T. &amp; White, J. M. Simulating chalcogen bonding using molecular mechanics: a pseudoatom approach to model ebselen. J. Mol. Model. 28, 66 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8867462</ArticleId><ArticleId IdType="pubmed">35201444</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, J. A. et al. ff14SB: improving the Accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696–3713 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821407</ArticleId><ArticleId IdType="pubmed">26574453</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendsen, H. J. C., van der Spoel, D. &amp; van Drunen, R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 91, 43–56 (1995).</Citation></Reference><Reference><Citation>Lindahl, E., Hess, B. &amp; van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 7, 306–317 (2001).</Citation></Reference><Reference><Citation>Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701–1718 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess, B., Kutzner, C., van der Spoel, D. &amp; Lindahl, E. GROMACS 4: algorithms for highly efficient, Load-Balanced, and Scalable Molecular Simulation. J. Chem. Theory Comput. 4, 435–447 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">26620784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronk, S. et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 29, 845–854 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605599</ArticleId><ArticleId IdType="pubmed">23407358</ArticleId></ArticleIdList></Reference><Reference><Citation>Markidis, S. &amp; Laure, E. Solving software challenges for exascalevol. 8759 (Springer International Publishing, 2015).</Citation></Reference><Reference><Citation>Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX . 1–2, 19–25 (2015).</Citation></Reference><Reference><Citation>Bussi, G., Donadio, D. &amp; Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 1-8 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17212484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess, B., Bekker, H., Berendsen, H. J. C. &amp; Fraaije, J. G. E. M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463–1472 (1997).</Citation></Reference><Reference><Citation>Miller, B. R. et al. MMPBSA.py: an efficient program for end-state Free Energy calculations. J. Chem. Theory Comput. 8, 3314–3321 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">26605738</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed, L. J. &amp; Muench, H. A simple method of estimating 50% endpoints. Am. J. Epidemiol. 27, 493–497 (1938).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>